LSP closes $280m life sciences venture fund

LSP 5 was announced and held its first close on €80m in October 2014. The VC held a second close in April 2015 and third in June 2015 on €137.5m.

Investors
The fund is backed by both new and existing investors, including institutional and private LPs from Europe and the US. It received commitments from pharmaceutical company Bristol-Myers-Squibb.

Investments
The fund is primarily focused on Europe and will invest in around 20 companies across the verticals of drug development, medical devices and diagnostics. It will invest in all stages of development, from early pre-clinical to later-stage.

Nine investments have been made by LSP 5 so far, including Irish medical device company Neuravi, Switzerland-based immuno-oncology company Nouscom, and Kuros Biosciences, recently listed on the Swiss Stock Exchange and focused on tissue repair and regeneration.

People
LSP – René Kuijten (managing partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Funds
• Venture
• Benelux
• Region
• Venture
• Life Science Partners
• Netherlands